Video

Dr. Goy Discusses Combinations in Mantle Cell Lymphoma

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combinations in mantle cell lymphoma.

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combinations in mantle cell lymphoma (MCL).

In addition to the progress seen with ibrutinib (Imbruvica) and acalabrutinib (Calquence), combinations have also created excitement in the treatment landscape of MCL. In addition to the acalabrutinib data presented at the 2017 ASH Annual Meeting, there were data presented on the combination of lenalidomide (Revlimid) plus rituximab (Rituxan), which showed that patients treated with this combination had a high rate of complete response (CR).

Goy says that combinations with biological agents may achieve a deeper response than monotherapy, and in a pilot study of rituximab plus lenalidomide and ibrutinib, the response rate was over 85% and the CR rate was 60%. This is promising for patients with relapsed or refractory MCL, Goy adds.

Additionally, there was a multicenter trial looking at the long-term follow-up of lenalidomide and rituximab in patients with MCL presented at ASH 2017. Goy says that although the study was small, the fact that some patients were still in remission after 5 years was interesting.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity